查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1908263

頭頸癌治療市場規模、佔有率和趨勢分析報告：按治療方法、給藥途徑、分銷管道、地區和細分市場預測（2026-2033 年）

Head And Neck Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

頭頸癌治療市場概覽

2025年全球頭頸癌治療市場規模估計為25.3億美元，預計2033年將達到62.5億美元。

預計從 2026 年到 2033 年，該市場將以 12.00% 的複合年成長率成長。這一市場成長歸因於頭頸癌發病率的上升、對標靶治療治療和免疫治療方法的需求增加以及診斷準確性的提高。

頭頸癌的發生率持續上升，推動了對標靶治療治療和免疫療法的需求不斷成長。在不斷湧現的臨床證據的支持下，診斷準確性正在迅速提高。例如，2025年6月，GORTEC的III期REACH研究報告稱， Avelumab聯合治療放射線治療合格Cisplatin治療的頭頸癌患者取得了良好的療效。該研究達到了其主要終點—改善無惡化生存期，並在500多名受試者中證實了良好的安全性。病患和醫護人員對頭頸癌的認知不斷提高，也促進了早期發現，並擴大了多重藥物合併治療策略的應用。同時，人們越來越傾向於微創和低毒性的治療方法，這推動了創新藥物的普及。此外，擴大臨床試驗規模和加快監管核准流程也提高了產品在全球主要市場的可近性。

人類乳突病毒 (HPV) 相關口咽癌發生率的不斷上升已成為市場成長的關鍵促進因素。這些 HPV 相關亞型對治療的反應往往各不相同，促使人們加大研發投入，並開發個人化治療方案。臨床指引擴大根據 HPV 感染狀態來區分治療方法，從而推動了精準醫療的需求。製藥公司正在投資研發以病毒致癌機制為核心的治療通訊協定，以擴大治療範圍。年輕成人 HPV 陽性病例的增加正在改變疾病的年齡分佈，並創造新的市場機會。公眾意識的提高和 HPV 相關惡性腫瘤篩檢，有助於早期診斷和治療。

在頭頸癌治療領域，聯合治療策略的應用日益普及，可望提高緩解率和存活率。將免疫療法與化療或標靶藥物結合的治療方法正在第一線治療和難治性病例中進行測試。例如，FDA於2025年6月核准Keytruda用於PD-L1陽性頭頸癌患者，這標誌著生物標記指導治療日益受到關注。此核准也凸顯了PD-L1陰性患者未被滿足的醫療需求。 CEL-SCI公司的Multikine旨在填補這一空白，無論PD-L1狀態如何，均可在標準治療前對患者進行治療。 Multikine旨在刺激早期免疫反應，是一種有望擴大治療範圍並改善不同患者群體預後的創新療法。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章 頭頸癌治療市場變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章 頭頸癌治療市場：依治療方法和業務分析

  • 按治療方法的市場佔有率（2025 年和 2033 年）
  • 按治療方法分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 化療
  • 免疫療法
  • 標靶治療

5. 依給藥途徑和業務分析分類的頭頸癌治療市場

  • 按給藥途徑分類的市場佔有率（2025 年和 2033 年）
  • 按給藥途徑分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 注射
  • 口服

6. 按通路和業務分析分類的頭頸癌治療市場

  • 按分銷管道分類的市場佔有率（2025 年和 2033 年）
  • 按分銷管道分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 零售藥房和專科藥房
  • 醫院藥房
  • 網路藥房

第7章 頭頸癌治療市場：區域、估算與趨勢分析

  • 區域市場佔有率分析（2025 年和 2033 年）
  • 區域市場概覽
  • 市場規模及預測趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭情勢

  • 參與公司概況
  • 企業市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/列表
    • Eli Lilly and Company
    • Sanofi
    • Merck & Co., Inc.
    • Cumberland Pharmaceuticals Inc.
    • Bristol-Myers Squibb Company
    • AstraZeneca
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • F. Hoffmann-La Roche Ltd.
Product Code: GVR-2-68038-125-2

Head And Neck Cancer Therapeutics Market Summary

The global head and neck cancer therapeutics market size was estimated at USD 2.53 billion in 2025 and is projected to reach USD 6.25 billion by 2033, growing at a CAGR of 12.00% from 2026 to 2033. The market is growing due to the rising incidence of head and neck cancers, increasing demand for targeted and immunotherapy-based treatments, and advancements in diagnostic precision.

The incidence of head and neck cancers continues to rise, driving greater demand for targeted therapies and immunotherapy-based treatment approaches. Diagnostic accuracy is improving rapidly, supported by new clinical evidence. For instance, in June 2025, GORTEC's Phase III REACH trial reported positive outcomes for avelumab combined with radiotherapy in cisplatin-ineligible head and neck cancer patients. The study achieved its primary endpoint of improved progression-free survival and showed a favorable safety profile in more than 500 participants. Increasing awareness among patients and healthcare providers is also strengthening early detection and expanding the use of multi-line treatment strategies. Meanwhile, the growing preference for minimally invasive, lower-toxicity options is boosting the adoption of innovative drug classes. In addition, ongoing clinical trial expansion and accelerated regulatory pathways are improving product accessibility across major global markets.

The growing prevalence of human papillomavirus (HPV)-associated oropharyngeal cancers is emerging as a significant driver for market growth. These HPV-related subtypes often respond differently to treatment, prompting a rise in research and tailored drug development. Clinical guidelines increasingly differentiate therapeutic approaches based on HPV status, fueling demand for precision therapies. Pharmaceutical companies are investing in treatment protocols that address viral oncogenesis, expanding the therapeutic landscape. The increasing incidence of HPV-positive cases among younger adults has shifted the disease demographic, creating new market opportunities. Enhanced public awareness and screening for HPV-related malignancies contribute to earlier diagnosis and treatment initiation.

Adopting combination therapy strategies is gaining momentum in the head and neck cancer therapeutics space, offering improved response rates and survival outcomes. Treatment regimens integrating immunotherapy with chemotherapy or targeted agents are being tested in both first-line and refractory settings. For instance, in June 2025, the FDA's approval of Keytruda for PD-L1-positive head and neck cancer patients highlights the growing focus on biomarker-based therapies. The announcement also emphasized the unmet need in PD-L1-negative patients. CEL-SCI's Multikine aims to address this gap by treating patients before standard therapies, regardless of PD-L1 status. Designed to stimulate an early immune response, Multikine represents a novel approach that could broaden treatment access and improve outcomes across diverse patient groups.

Global Head And Neck Cancer Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global head and neck cancer therapeutics market report based on therapy, route of administration, distribution channel, and region:

  • Therapy Outlook (Revenue, USD Million, 2021 - 2033)
  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Injectable
  • Oral
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Retail and Specialty Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Therapy
    • 1.2.2. Route of Administration
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Head and Neck Cancer Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Head and Neck Cancer Therapeutics Market: Therapy Business Analysis

  • 4.1. Therapy Market Share, 2025 & 2033
  • 4.2. Therapy Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Therapy, 2021 to 2033 (USD Million)
  • 4.4. Chemotherapy
    • 4.4.1. Chemotherapy Market, 2021 - 2033 (USD Million)
  • 4.5. Immunotherapy
    • 4.5.1. Immunotherapy Market, 2021 - 2033 (USD Million)
  • 4.6. Targeted Therapy
    • 4.6.1. Targeted Therapy Market, 2021 - 2033 (USD Million)

Chapter 5. Head and Neck Cancer Therapeutics Market: Route of Administration Business Analysis

  • 5.1. Route of Administration Market Share, 2025 & 2033
  • 5.2. Route of Administration Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Route of administration, 2021 to 2033 (USD Million)
  • 5.4. Injectable
    • 5.4.1. Injectable Market, 2021 - 2033 (USD Million)
  • 5.5. Oral
    • 5.5.1. Oral Market, 2021 - 2033 (USD Million)

Chapter 6. Head and Neck Cancer Therapeutics Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2025 & 2033
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution channel, 2021 to 2033 (USD Million)
  • 6.4. Retail and Specialty Pharmacies
    • 6.4.1. Retail and Specialty Pharmacies Market, 2021 - 2033 (USD Million)
  • 6.5. Hospital Pharmacies
    • 6.5.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 7. Head and Neck Cancer Therapeutics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. U.S. Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. Uk Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Japan Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. China Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Eli Lilly and Company
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Therapy Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Sanofi
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Therapy Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Merck & Co., Inc.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Therapy Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Cumberland Pharmaceuticals Inc.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Therapy Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Bristol-Myers Squibb Company
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Therapy Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. AstraZeneca
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Therapy Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Takeda Pharmaceutical Company Limited
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Therapy Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Teva Pharmaceutical Industries Ltd.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Therapy Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. F. Hoffmann-La Roche Ltd.
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Therapy Benchmarking
      • 8.5.9.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global head and neck cancer therapeutics market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 5 Global head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 6 Global head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 7 North America head and neck cancer therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 9 North America head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 10 North America head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11 U.S. head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 12 U.S. head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 13 U.S. head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 14 Canada head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 15 Canada head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 16 Canada head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 17 Mexico head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 18 Mexico head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 19 Mexico head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20 Europe head and neck cancer therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 21 Europe head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 22 Europe head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 23 Europe head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24 UK head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 25 UK head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 26 UK head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 27 Germany head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 28 Germany head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 29 Germany head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 France head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 31 France head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 32 France head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 33 Italy head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 34 Italy head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 35 Italy head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 36 Spain head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 37 Spain head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 38 Spain head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39 Norway head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 40 Norway head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 41 Norway head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 42 Denmark head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 43 Denmark head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 44 Denmark head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45 Sweden head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 46 Sweden head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 47 Sweden head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific head and neck cancer therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD
  • Table 50 Asia Pacific head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52 Japan head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 53 Japan head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 54 Japan head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 55 China head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 56 China head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 57 China head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 58 India head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 59 India head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 60 India head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61 Australia head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 62 Australia head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 63 Australia head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 64 South Korea head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 65 South Korea head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 66 South Korea head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 67 Thailand head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 68 Thailand head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 69 Thailand head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 70 Latin America head and neck cancer therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 71 Latin America head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 72 Latin America head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 73 Latin America head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 74 Brazil head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 75 Brazil head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 76 Brazil head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 77 Argentina head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 78 Argentina head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 79 Argentina head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 80 Middle East & Africa head and neck cancer therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 81 Middle East & Africa head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 84 South Africa head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 85 South Africa head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 86 South Africa head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 90 UAE head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 91 UAE head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 92 UAE head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 93 Kuwait head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 94 Kuwait head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 95 Kuwait head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Head and neck cancer therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Head and neck cancer therapeutics market dynamics
  • Fig. 12 Head and neck cancer therapeutics market: Porter's five forces analysis
  • Fig. 13 Head and neck cancer therapeutics market: PESTLE analysis
  • Fig. 14 Therapy market, 2021 - 2033 (USD Million)
  • Fig. 15 Chemotherapy market, 2021 - 2033 (USD Million)
  • Fig. 16 Immunotherapy market, 2021 - 2033 (USD Million)
  • Fig. 17 Targeted therapy market, 2021 - 2033 (USD Million)
  • Fig. 18 Route of administration market, 2021 - 2033 (USD Million)
  • Fig. 19 Injectable market, 2021 - 2033 (USD Million)
  • Fig. 20 Oral market, 2021 - 2033 (USD Million)
  • Fig. 21 Distribution channel market, 2021 - 2033 (USD Million)
  • Fig. 22 Retail and Specialty Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 23 Hospital pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 24 Online pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 25 Head and neck cancer therapeutics market revenue, by region
  • Fig. 26 Regional marketplace: Key takeaways
  • Fig. 27 North America Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 28 U.S. country dynamics
  • Fig. 29 U.S. Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 30 Canada country dynamics
  • Fig. 31 Canada Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 32 Mexico country dynamics
  • Fig. 33 Mexico Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 34 Europe Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 35 UK country dynamics
  • Fig. 36 UK Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 37 Germany country dynamics
  • Fig. 38 Germany Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 39 France country dynamics
  • Fig. 40 France Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 41 Italy country dynamics
  • Fig. 42 Italy Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 43 Spain country dynamics
  • Fig. 44 Spain Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 45 Norway country dynamics
  • Fig. 46 Norway Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 47 Sweden country dynamics
  • Fig. 48 Sweden Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 49 Denmark country dynamics
  • Fig. 50 Denmark Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 51 Asia Pacific Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 52 Japan country dynamics
  • Fig. 53 Japan Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 54 China country dynamics
  • Fig. 55 China Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 56 India country dynamics
  • Fig. 57 India Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 58 Australia country dynamics
  • Fig. 59 Australia Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 60 South Korea country dynamics
  • Fig. 61 South Korea Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 62 Thailand country dynamics
  • Fig. 63 Thailand Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 64 Latin America Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 65 Brazil country dynamics
  • Fig. 66 Brazil Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 67 Argentina country dynamics
  • Fig. 68 Argentina Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 69 MEA Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 70 South Africa country dynamics
  • Fig. 71 South Africa Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 72 Saudi Arabia country dynamics
  • Fig. 73 Saudi Arabia Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 74 UAE country dynamics
  • Fig. 75 UAE Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 76 Kuwait country dynamics
  • Fig. 77 Kuwait Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 78 Company categorization
  • Fig. 79 Company market position analysis
  • Fig. 80 Strategic framework